Department of Cardiovascular Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; and.
Department of Anatomy, Faculty of Basic Medicine, Henan Medical College, Zhengzhou, China.
J Cardiovasc Pharmacol. 2020 Jan;75(1):75-83. doi: 10.1097/FJC.0000000000000760.
Myocardial infarction (MI) is one of the higher mortality rates, and current treatment can only delay the progression of the disease. Experiments have shown that cell therapy could improve cardiac function and mesenchymal stem cells (MSCs)-based therapies provide a great promising approach in the treatment of MI. However, low cell survival and engraftment restricts the successful application of MSCs for treating MI. Here, we explored whether co-transplantation of a chitosan (CS) thermosensitive hydrogel with bone marrow-derived MSCs (BMSCs) could optimize and maximize the therapeutic of BMSCs in a mouse model of MI. The fate of transplanted BMSCs was monitored by bioluminescence imaging, and the recovery of cardiac function was detected by echocardiogram. Our results proved that CS hydrogel enhanced the BMSCs' survival and the recovery of cardiac function by protecting the vascular endothelial cells. Further studies revealed that the increased number of vascular endothelial cells was due to the fact that transplanted BMSCs inhibited the inflammatory response and alleviated the pyroptosis of vascular endothelial cells. In conclusions, CS hydrogel improved the engraftment of transplanted BMSCs, ameliorated inflammatory responses, and further promoted functional recovery of heart by alleviating vascular endothelial cell pyroptosis.
心肌梗死（MI）是死亡率较高的疾病之一，目前的治疗方法只能延缓疾病的进展。实验表明，细胞疗法可以改善心脏功能，间充质干细胞（MSCs）为治疗 MI 提供了很有前途的方法。然而，细胞存活率和植入率低限制了 MSCs 成功应用于治疗 MI。在这里，我们探讨了壳聚糖（CS）温敏水凝胶与骨髓来源的间充质干细胞（BMSCs）共移植是否可以优化和最大化 BMSCs 在 MI 小鼠模型中的治疗效果。通过生物发光成像监测移植的 BMSCs 的命运，并通过超声心动图检测心脏功能的恢复。我们的结果证明，CS 水凝胶通过保护血管内皮细胞来增强 BMSCs 的存活和心脏功能的恢复。进一步的研究表明，血管内皮细胞数量的增加是由于移植的 BMSCs 抑制了炎症反应并减轻了血管内皮细胞的细胞焦亡。总之，CS 水凝胶通过减轻血管内皮细胞的细胞焦亡，改善炎症反应，进一步促进心脏功能的恢复，从而提高了移植的 BMSCs 的植入率。
